** Neo-Adjuvant - Squamous Cell Carcinoma

**SUSPENDED** UCI 16-01 (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

**SUSPENDED** UCI 16-72 Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Ejadi)

** Adjuvant – Squamous Cell Carcinoma

RTOG-0920 Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (Daroui)

** Neo-Adjuvant - Nasopharyngeal

NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Ejadi)

** Opening soon
For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

** Opening soon            0218

UCI 16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

UCI 17-58** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)